|Bid||67.34 x 1200|
|Ask||67.58 x 1800|
|Day's Range||66.77 - 67.57|
|52 Week Range||56.56 - 78.94|
|Beta (5Y Monthly)||0.40|
|PE Ratio (TTM)||280.62|
|Earnings Date||Jul 28, 2021 - Aug 02, 2021|
|Forward Dividend & Yield||2.84 (4.26%)|
|Ex-Dividend Date||Jun 14, 2021|
|1y Target Est||74.49|
Biotech Enochian BioSciences (NASDAQ: ENOB) enjoyed a nice share price lift on Monday. Enochian explained that this technique is effected through a nanoparticle, which gives scope for either rapid treatment of an infection, or an "ambush" in which it effectively waits in a cell for infection, then strikes. This technology was developed by the biotech's co-founder Serhat Gumrukcu.
Gilead Sciences Inc said an analysis showed its antiviral remdesivir reduced mortality rates in hospitalized patients with COVID-19 and increased the likelihood of being discharged by day 28 after a five-day course of the treatment. The drugmaker said on Monday it analyzed data from 98,654 patients from three retrospective studies of the real-world treatment of hospitalized COVID-19 patients. Gilead said the results were consistently observed at different timeframes over the course of the pandemic and across geographies.
Shares of Gilead Sciences Inc. gained 0.3% in premarket trading on Monday after the drug manufacturer said retrospective research shows that Veklury, its COVID-19 treatment, reduces mortality among people who have been hospitalized with COVID-19. Veklury, which received full approval from the Food and Drug Administration last year, can be prescribed to people who have COVID-19, are hospitalized and are at least 12 years old. The new research examined real-world data from three databases that inc